Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TET3 | O43151 | 1/20 | 0.45 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.45 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.45 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032506 | 0.84 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18068774 | 0.84 | OPRM1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2636624 | 0.81 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13774957 | 0.81 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6030899 | 0.78 | MEN1 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6032348 | 0.77 | AR (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6032510 | 0.77 | SMN1; SMN2 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8324812 | 0.76 | OPRM1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3543988 | 0.75 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6032542 | 0.75 | CA12 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | claimed |
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | NR1H2, NR1H3, RXRG | CA12 4836/4885CA1 4863/4885CA2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.